In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy(519 views) Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M
Affiliations: Via Modigliani 66/68, Aversa (CE), 81031, Italy
References: Not available.
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy
Many tumors with neuroendocrine characteristics express high amounts of somatostatin receptors that enable in vivo imaging with [111In-DTPA-D- Phe1]-octreotide. In this study, we have analyzed the feasibility in detecting and characterizing thymic masses by somatostatin receptor scintigraphy (SRS). Methods: Eighteen patients (13 women, 5 men, ages 18-78 yr; mean ± s.d. = 42.1 ± 17.6 yr) were enrolled in this study. Eleven patients were studied during diagnosis and seven during routine follow-up. In seven patients, myasthenia gravis was the presenting symptom. SRS was performed within 4 wk after CT and/or MRI. Planar and tomographic images were acquired within 24 hr after the injection of approximately 111 MBq of [111In-DTPA-D-Phe1]-octreotide. The scintigraphic results were categorized according to the histologic findings. Results: Histology diagnosed 10 mixed epithelial/lymphoid thymomas (8 with prevalent epithelial component), 2 thymic carcinomas, 1 thymic carcinoid, 1 lymphangioma and 4 thymic hyperplasias. Two thymoma were Stage I, 3 were Stage II, 2 were Stage III and 5 were Stage IV, as was the thymic carcinoid. Indium-111-DTPA-D- Phe1-octreotide concentrated in primary and/or metastatic sites of thymic tumors, thereby enabling successful external gamma imaging of sites greater than 1.5 cm in size. Tumor-to-lung (T/L) ratios were as high as 7.6-fold (range 1.7-7.6). Untreated thymomas showed higher T/L (4.34 ± 1.57) than treated ones (2.68 ± 1.18). No uptake was detectable in the four patients with benign thymic hyperplasia and the patient with the lymphangioma. Conclusion: Indium-111-DTPA-D-Phe1-octreotide is avidly concentrated within thymic tumors, but it is not concentrated by thymic hyperplasia, which allows differential diagnosis. Thus, in patients with myasthenia gravis, SRS may have a role in characterizing thymic masses, thereby overcoming the limits of cross-sectional imaging modalities.
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy
No results.
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy
Aloj L, Aurilio M, Rinaldi V, D'Ambrosio L, Tesauro D, Peitl PK, Maina T, Mansi R, Von Guggenberg E, Joosten L, Sosabowski JK, Breeman WA, De Blois E, Koelewijn S, Melis M, Waser B, Beetschen K, Reubi JC, De Jong M * The EEE project(564 views) Proc Int Cosm Ray Conf Icrc Universidad Nacional Autonoma De Mexico, 2007; 5(HEPART2): 977-980. Impact Factor:0 ViewExport to BibTeXExport to EndNote